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Worldwide, many infections caused by viruses, bacteria
or parasites are known to be tick-transmitted zoonoses,
i.e. infections transmitted from animals to humans. The
present review covers zoonoses which are known to
be or suspected to be tick-transmitted in large parts
of Europe, i.e. Lyme borreliosis (LB), tick-borne
encephalitis (TBE) , ehrlichiosis and babesiosis, while
other infections, which can or might be tick-trans-
mitted or are only present in localized geographic areas,
e.g. Q fever, tuleremia and Mediterranean spotted
fever, are not discussed.
Tick-borne zoonoses as a cause of human disease
have been known for many years but the major impact
on public health in Europe and in the USA was first
recognized by identification of Borrelia burgdoifCri as the
cause of Lyme disease in the early 1980s. Since then,
LB has emerged as the most common and significant
arthropod-transmitted zoonosis in these parts of the
world.
LYME BORRELIOSIS
LB is caused by a cultivable spirochete, a new species
of the genus Borrelia (family Spirochaetaceae), trans-
mitted by hard ticks (Ixodidae) of the genus Ixodes. In
Europe, the vector is Ixodes ricinus. Animal reservoirs
are small animals (rodents) but large animals, e.g. deer,
cattle and horses, are important for the life cycle of the
tick. The causative agent of LB was isolated by and
named after Willy Burgdorfer in the USA [1,2].
Later, it was found that LB has a wider clinical
spectrum in Europe than in the USA, and this was
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shown to be due to the presence in Europe of at least
three genospecies of B. burgdoiferi sensu lato, i.e. B.
burgdoiferi sensu stricto, B. garinii and B. aJzelii, as
compared to the one genospecies, B. burgdoifCri sensu
stricto, in the USA [3-5]. Of the genospecies, B. cifzelii
has predominantly been associated with acrodermatitis
chronica atrophicans, B. garinii with neurologic mani-
festations and B. burgdoiferi sensu stricto with arthritis,
while erythema migrans is caused by all three geno-
species.
A majority bf the clinical manifestations of B.
burgdoifCri sensu lato infection, e.g. erythema chronicum
migrans or erythema migrans (EM), lymphocytoma
benigna cutis, acrodermatitis chronica atrophicans
(ACA), meningopolyneuritis and a connection between
EM and meningitis were first described many years ago
by European clinicians [6-11]. Use of penicillin for
treatment of EM was described in the early 1950s
by Swedish physicians [12,13]. In the same decade,
German physicians established, by studies in volunteers,
that both EM and ACA were caused by a transmissible
agent [14,15]. These and other European physicians
also suggested a spirochetal etiology, and treatment
of chronic meningitis by penicillin was shown to be
efficient [16]. However, it was not until a disease,
dominated by the clinical manifestation ofarthritis, was
noted in Lyme, Connecticut, USA, that the causative
agent was recognized [17].
LB has been reported from all European countries
but national surveillance methods, when in place, vary
between countries in Europe and do not allow for
comparisons of disease incidence rates [18]. The USA,
with a federal epidemiologic surveillance organization,
reports a major increase in disease incidence over the
past 10 years, as well as an expansion of the disease to
previously less affected or unaffected areas [19]. The
increase in and expansion of the disease is presumed to
be due to the rapid increase in the number of white-
tailed deer, with an increased presence in densely
populated areas [20]. No certain data are available from
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Europe but a corresponding increase in the roe deer
population has been noted, e.g. in Scandinavia [21 J, as
well as an expansion of its distribution limits. An
increase in disease incidence is, therefore, likely to have
occurred also in Europe.
The incidence of LB in a general population has
only been determined in one study, conducted in
southern Sweden [22]. The study, conducted in an area
comprising 11% of Sweden and in 24% (2.13 million)
of the Swedish population, reported an average yearly
incidence rate of 69 cases per 100 000 inhabitants,
with a range of 26-160 cases per 100000. The most
common manifestation was EM (77% of all cases),
followed by neuroborreliosis (16%) and arthritis (7%);
carditis was rare.
Although the above study is the only one available
on disease incidence, indirect measures such as pre-
valence of Ixodes ricinus ticks, B. burgdoiferi sensu lato
infection rate in ticks and seroprevalence studies are
available from most parts of Europe [18J. All of
the indirect measures have, however, weaknesses as
indicators of LB. Tick prevalence data give a rough
estimate of disease prevalence; for example, low tick
prevalence corresponds to low incidence of disease in
northern Scandinavia [23J but high tick prevalence
rates may not be followed by known, high disease rates,
e.g. in Ireland (24], due to a number of confounding
factors. Similarly, B. burgdoiferi sensu lato infection
rates in ticks generally correspond to known disease
incidence rates within a country [23) but reported rates
may not be comparable between investigators, due to
methodological differences. Intensity of infection in
ticks seems, however, to increase from west to east
in Europe (J. Gray, personal communication). Sero-
prevalence represents probably the best indirect measure
of disease incidence but, again, these studies are difficult
to interpret on a European scale, due to methodological
differences and because ofa lack ofcorrelation between
seroprevalence and disease incidence.
Bearing these problems in mind, the disease seems
to show a gradient of increasing incidence from west
to east, although pockets of high-endemic areas are
present also in low-endemic countries [24-36J. Also, a
gradient of decreasing incidence from south to north
(and east to west) in northern Europe [37-55J and from
north to south in Italy, Spain and Greece has been
noted [56-71]. The highest incidence rates are reported
from central and eastern Europe, e.g. an average rate
of LB of 300 per 100 000 inhabitants from Austria,
with 350 per 100000 inhabitants for the eastern and
southern states of Wien, Niederosterreich, Steiermark
and Kirnten [72-91J.
Seroprevalence and disease incidence rates are also
increased in certain occupations, e.g. forestry workers
157
[72,74, 92-102J, in some recreational occupations, e.g.
orienteers [74], and in tourists to high-endemic areas
both in Europe and to the east coast of the USA
[24,27J. Seroprevalence in orienteers which is com-
parable to that found in the general population has,
however, also been reported from Sweden, where the
use of protective clothing is strictly enforced [23J.
Seroprevalence and disease incidence rates are
influenced by gender, most studies reporting higher
rates for males, presumed to be due to higher occupa-
tional risks and outdoor recreational activities [103].
Seroprevalence, incidence and, most notably, disease
manifestations are also influenced by age, with children
showing both high incidence rates and markedly
different distribution of disease manifestations from
those seen in adults; for example, children have more
neurologic, disease than adults [103-108].
Seroprevalence studies in large proportions of the
general population are not available from any European
country. Some studies offer seroprevalence data from
blood donors [109-111], but results are again limited
to certain areas ofa country and are difficult to compare
between countries, or even laboratories, due to
methodological differences. An ongoing seroprevalence
study based on blood-donor sera in Sweden, the only
country which also has a population-based incidence
study, seems to yield a correlate between seroprevalence
and disease incidence, which could be used for
estimates of disease incidence in other countries (own
unpublished data).
Treatment strategies for LB vary between countries
and physicians but several regimens are useful. Preven-
tion is currently based on protection against tick bite
but two vaccines, both based on the outer surface
protein A (Osp A) of B. burgdoiferi sensu stricto, are
currently undergoing efficacy trials in the USA, and
preliminary data indicate that this type of vaccine is
protective (S. Plotkin, personal communication). It is,
therefore, likely that a similar vaccine will eventually
be available also in Europe, although manufacturing
will be more complex, since the vaccine will have to
include Osp A from at least the other known geno-
species, B. ajzelii and B. garinii, in addition to the Osp
A of B. burgdoiferi sensu stricto used in the US trials.
B. burgdoiferi sensu lato has been isolated from
numerous tissues, e.g. skin, cerebrospinal fluid and
synovial fluid but the diagnostic sensitivity of culture is
low. PCRs have also been described but the results have
been variable and, in many cases, conflicting [112].
The most commonly used diagnostic method in LB is
serology, including antibody detection in cerebrospinal
fluid. At first, immunofluorescence (IF) and, later,
enzyme-linked immunosorbent assay (ELISA] were
developed. These ELISAs, based on sonicate antigens,
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were later followed by ELISAs based on purified
antigens, e.g. a flagellar antigen or recombinant antigens
[113-117]. Immunoblot or Western blot, following
screening by ELISA, has recently been recommended
as a confirmatory assay in the USA [118]. It should be
noted, however, that neither ELISA nor immunoblot
for IgG will differentiate current infection from
previous clinical or asymptomatic infections; there is
thus a lack of specificity for active infection, which
represents a greater diagnostic problem in high-endemic
areas than lack of specificity of the assays as such.
In Europe, immunoblot is used in some reference
laboratories but ruost routine laboratories rely on
ELISA. The difference in practices is probably due to
the better performance oflater-generation commercial
ELISA kits with high cut-off levels used in Europe,
which seem to have avoided diagnostic problems of
similar magnitude to those encountered in the USA.
Also, before immunoblot can be recommended on a
larger scale, further clarification of the importance of
the phenotypic heterogeneity of B. burgdoiferi isolates in
Europe and the definition of common European
immunoblot criteria seems to be needed.
The European Union, recognizing the need for a
joint effort in the field of Lyme disease, supported a
Concerted Action on Lyme Borreliosis (EUCALB;
coordinated by Dr Jeremy Gray). This network of
scientists and clinicians from 17 European countries
investigated disease transmission, diagnostics and clinical
aspects of the disease. The network has addressed,
among other issues, the need for standardization of
serodiagnosis by launching a quality assurance scheme
and by an immunoblot study to establish common
European criteria. In collaboration with the WHO, the
network contributed to serodiagnostic recommenda-
tions [119]. Also, European case definitions and
laboratory support for diagnosis have been published
[120] and information on different aspects of LB in
Europe has been made available on the Internet
(http://www.dis.strath.ac.uk/lymeeu/).
TICK-BORNE ENCEPHALITIS
The disease is caused by tick-borne encephalitis virus
(TBEV) of the family Flaviviridae, genus Flavivirus
(formally group B arbovirus), a family including many
other known arthropod-borne viruses, e.g. those
causing yellow fever, dengue and Japanese encephalitis.
Two subtypes of TBEV are recognized, one European
and one Far Eastern, transmitted by Ixodes ricinus and
Ixodes persulcatus, respectively. The distributions of the
two related tick species overlap in north-eastern Europe
but, in general, the vector of TBEV is 1. ricinus in
western and central Europe and 1. persulcatus in the
European parts of Russia. Host reservoirs with regard
to mammals and rodents are the same as for B.
burgdoiferi sensu lato. Since TBE has been the subject of
two recent, extensive reviews [121,122], only some
facts on the virus, i.e. the disease, epidemiology,
diagnostics and prevention, will be summarized here.
TBE is a major cause of morbidity in central,
eastern and northern Europe [23,78,121-142]. West of
a sharp demarcation line running from mid-Sweden
though mid-France, the disease is rare or non-existent.
Disease incidence increases, as for LB, from west to east,
with a highest reported rate of 184 per 100 000.
Seroprevalence rates as high as 22-83% have been
reported from some areas [23,78,127,138].
The disease with meningoencephalitic manifesta-
tions was first described from Austria in 1927 and from
Russia in 1932. The virus was fIrSt isolated from human
tissue in 1937 and the prototype strain for the western
subtype, Neudoerfl, was isolated from a tick in Austria
in 1971. TBEV has three major proteins, a structural
protein C (Core or V2) and two glycoproteins of
the envelope, the hemagglutinin E (or V3) and the
membrane M (Vl) proteins. The C and E proteins are
stable and identical for both the western and the eastern
subtypes, while the M protein varies with the isolates.
As for LB, most of the infections [60-70%] are
subclinical. In clinical cases, the incubation period is
usually 7-14 days and the first viremic stage with flu-
like symptoms lasts generally for 2-8 days. This first
phase of a biphasic disease is reported by some 60-70%
of patients who later go on to develop the second,
neurologic stage. An abortive infection after the first
stage is seen in a majority of the clinical cases. The
second stage is found in 5-30% of cases with clinical
disease, and the manifestations vary from pure menin-
gitis to meningoencephalitis, with or without paralysis.
Reported mortality rates for the western subtype of
TBEV infection vary between 0% and 4% [121,123,
125,128-130].
The disease is relatively mild in children and both
the severity of the disease and the risk for permanent
sequelae increase with age [121,137]. The reported
rates of long-term sequelae vary between 2-11 % for
permanent paresis (121,124,126,131,135,138], 7-14%
for hearing defects [121], and 0-24% for cerebellar
dysfunction [121,124,135,138]. In carefully conducted
follow-up studies, postencephalitic symptoms were
found in 36-58% of patients and were classified in a
majority of cases as moderate to severe [121,135,138].
Laboratory diagnosis of the disease relies mainly on
serology. The first assays, still in general use, were the
complement-fixation (CF) and the hemagglutination-
inhibition (HI) tests, introduced in the late 1950s
[123,143]. Both methods allow for confirmation of the
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diagnosis within 1-2 weeks after onset of symptoms.
Early diagnosis can be achieved by demonstration of
IgM antibodies [144,145]. An indirect ELISA assay for
IgM and IgG antibodies is commercially available
[146,147]. The neutralization test (NT) can also be
used but the usefulness of the assay is mainly for
determination of antibody responses after vaccination.
In general, these assays are considered specific and
reliable for diagnosis of TBE. However, a recent study
showed that significant amounts of antibodies reactive
in the TBE ELISA and HI tests, but not in the NT, are
induced by yellow fever vaccination and/or dengue
fever infection [148].
No specific treatment is available for this devastating
infection. Prophylaxis and post-exposure prophylaxis
with specific immunoglobulin can be given up to the
fourth day ofpresumed exposure [149]. Vaccine against
TBEV has been available for many years but an im-
proved version was introduced in 1980 and has a
protective efficacy of 97% [150,151]. Currently, two
manufacturers provide a vaccine against TBEV [150,
152]. Simultaneous administration of both immuno-
globulin and vaccine has also been documented [152].
Mass vaccination campaigns have been performed in
Austria and in southern Germany, and the vaccine
is also widely used in other endemic countries [153].
A cost-benefit analysis of mass vaccination gave favor-
able results in Austria [154] and a vaccine strategy could
be considered also in countries with lower disease
incidence rates [121].
EHRLlCHIOSIS
The genus Ehrlichia (family Rickettsiaceae), named in
honor of the German bacteriologist Paul Ehrlich,
consists of obligate intracellular pathogens that invade
white blood cells. Ehrlichiae e.re known to cause disease
in animals in Europe but were not known or considered
as likely human pathogens on this continent until
recent research, conducted in the USA, identified
ehrlichiosis as an emergent, tick-borne zoonosis.
Monocytic ehrlichiosis
In 1986, infection with an Ehrlichia species was recog-
nized in a patient at Fort Chaffee, Arkansas, USA, by
characteristic morulae (inclusion bodies) in circulating
mononuclear cells and by a significant antibody response
to E. canis antigen [155]. The causative agent was
isolated in 1991 [156] and was shown by 16S RNA to
be closely related but not identical to E. canis. It was
classified as a species of its own, named E. chaffeensis.
Several recent American reviews give extensive in-
formation on the disease [157-159]. Therefore, only
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a summary will be presented here, with special reference
to our current knowledge of the situation in Europe.
Infection in humans varies from subclinical to
fulminant, with an estimated fatality rate of approxi-
mately 2% and a reported hospitalization rate of 40%
for clinical cases. In the USA, more than 400 clinical
cases have been recognized. However, most of the
infections seem, as for LB, to be subclinical, abortive or
mild. The most common clinical manifestation is a flu-
like illness with fever, malaise and myalgia [160].
Common laboratory findings include leukopenia,
thrombocytopenia, anemia and elevated liver trans-
aminases [157-160]. The treatme~t of choice is doxy-
cyclin.
Severe disease manifestations reported were respira-
tory insufficiency, i.e. adult respiratory distress syn-
drome (ARDS), renal failure and severe hepatic disease.
Serious neurologic involvement was manifested by
seizures, coma and lesions on autopsy with pleocytosis,
increased protein and E. chaffeensis antigen by PCR
in the cerebrospinal fluid [159]. A seronegative, fatal
case ofE. cheiffeensis infection in an HIV-positive patient
has been described [161]. Persistent infection, a
characteristic of ehrlichial infections in animals, has also
been demonstrated in a patient [162]. No cases of
blood-transfusion-transmitted infections are known.
Annual incidence rates of 3-5 per 100 000 have
been estimated in the endemic areas of the southern
USA but few population-based studies are available.
In a heavily tick-infested area of Arkansas, a 1.3%
seroconversion rate during a period of 1-4 weeks was
reported in military personnel [163]. Infection rates in
ticks of up to 32.5% have been reported [164].
In Europe, virtually nothing is known of either the
incidence or the prevalence of the disease, but a few
cases of E. chaffeensis infection have been reported
[165-167]. Also, two individuals with low levels of
antibody to E. chaffeensis antigen were detected in a
serosurvey on the west coast ofSweden [168]. All ofthese
cases or infections were identified by serology alone.
In the USA, the vector most consistently associated
with the disease is Amblyoma americanum [70], the lone
star tick, which is not present in Europe. Ehrlichiae
have been demonstrated by PCR in adult Amblyoma
americanum ticks (but not in nymphs) in several states
and, in one case in Arkansas, in Dermacentor variabilis
(the American dog tick). Clinical cases occurring out-
side the habitats of the above ticks indicate possible
additional vectors and/or related ehrlichial species.
The vector in Europe remains unknown. Also, it is
unclear whether the reported human cases or sero-
positive individuals found in Europe were infected
by E. chaffeensis or if these serologically diagnosed
individuals were infected by other ehrlichial species,
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showing inununological cross-reaction with E. ch'!ffeensis
antigen.
The animal reservoirs and susceptible hosts are,
as yet, not fully identified in the USA. The white-tailed
deer is susceptible to experimental infection, and popu-
lations of deer show high rates of antibodies to E.
chaffeensis in endemic areas. Experimentally infected
dogs, like the white-tailed deer, show persistent
infection. The role of rodents in the transmission cycle
remains to be elucidated [159].
The first laboratory assays using IF used E. canis-
infected mononuclear cells but, when slides with E.
chaffeensis antigen became available, E. canis was found
to be less sensitive. Currently, E. chaffeensis-infected
cells are used for IF and reagents are commercially
available [156,169]. Patients infected with E. chaffeensis
seem to seroconvert during the second week of the
disease and, unlike antibodies to LB, the antibodies to
E. chaffeensis measured by IF return to baseline levels
within 2 years after disease (S. Standaert, personal
communication). Immunoblot studies indicate immu-
nodominant proteins of 120, 29, 28 and 22 kDa [170].
No ELISA has been described for E. chaffeensis. PCR
was introduced early for diagnosis ofhuman disease and
represents a valuable method for rapid confirmation of -
the disease in suspected cases [159].
Granulocytic ehrlichiosis
In 1994, human infection with a granulocytic ehrlichia
was described from the northern, midwestern USA
[171,172]. IF and PCR demonstrated that the disease
was caused by an agent related to or identical with E.
equi and E. phagocytophila, two well-known agents of
veterinary diseases both in the USA (E. equt) and in
Europe (both agents). DNA homology studies have
shown 99.9% and 99.8% homology to these agents,
respectively. The homology of the new agent to the
monocytic E. chaffeensis was only 92.5% [172].
The agent of human granulocytic ehrlichiosis
(HGE) is currently unnamed, since it remains unclear
whether it represents a new species or whether the
human infection is caused by E. equilE. phagocytophila.
The relation between the three agents causing granulo-
cytic ehrlichiosis is also unclear. The main difference
between E. equi and E. phagocytophila seems to reside in
host specificity [173], but small differences in the 16S
rRNA sequences between the three have also been
noted [174,175]. A horse experimentally infected
with the HGE agent developed symptoms as of E. equi
infection and was resistant to subsequent challenge with
E. equi [176].
As for E. chaffeensis infection, recent American
reviews give extensive information on granulocytic
ehrlichiosis [157-159]. Therefore, only a summary will
be presented here, with special reference to our current
knowledge of the situation in Europe. Since HGE was
described recently, only some 70 clinical cases have
been diagnosed in the USA. Also as for E. chaffeensis
infection, clinical disease seems to vary from subclinical
to fulminant, with an estimated fatality rate of approxi-
mately 7-10% in clinical cases. The most common
clinical manifestation of HGE is, as for E. chaffeensis
infection, a flu-like disease [159]. In addition, infection
causes thrombocytopenia, leukopenia and elevated
transaminases in a majority of clinical cases.
Cases of HGE have been described from the
north-midwestern and north-eastern states ofthe USA.
A recent report indicates an incidence rate of 9-15% in
patients with symptoms conipatible with HGE in the
midwestern USA or an estimated minimum incidence
of 3 per 100000 [177]. The vector seems to be the
same as for LB, i.e. 1. scapularis, in the eastern and
midwestern USA. Tick-infection rates with the HGE
agent ofl0% in the midwest and up to 50% on the east
coast have been reported [159,164].
The transmission cycle of the HGE agent has not
been fully elucidated. The white-tailed deer seems to
represent a likely reservoir [159] but the role of rodents
remains to be clarified. Also, modes of transmission
other than tickbites, e.g. from blood of deer, have been
suggested [178].
Infection of humans with the HGE agent has
recently been reported from Europe, where 12 of 70
(17.1 %) Swiss LB patients were found to be seropositive
for the HGE agent [179]. HGE agent infection in LB
patients and in tick-exposed individuals in the UK has
been shown [180]. A study from Norway showed
10.2% seropositives among LB patients [181]. Similarly,
3.8% of LB patients from Denmark were seropositive
for the HGE agent (K. Hansen, personal communi-
cation). A seroprevalence study [168] in a tick-infested
area of south-western Sweden showed 21 of 185
(11.4%) HGE seropositives in a general population
where the rate for LB seropositives was 25 of 185
(13.5%). These studies indicate that HGE is a common
tick-borne infection in Europe.
In Europe, the vector of the HGE agent has not
been previously identified, although 1. ricinus is a
likely candidate. 1. ricinus is the known vector of E.
phagocytophila in Europe. Also, 1. ricinus is closely related
to 1. scapularis, the vector of LB in Europe and in the
USA, respectively. We have recently demonstrated, by
PCR and 16S rRNA sequence analysis, the presence
of the agent in Swedish 1. ricinus ticks at a similar rate
as in the mid-western USA (own unpublished data).
The animal reservoirs have not yet been established but
the HGE agent has been identified as a conunon cause
ofclinical disease in Swedish dogs and horses [174,182].
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The diagnosis of HGE is based on IF with E. equi
or E. phagocytophila antigen for antibodies to the HGE
agent [159]. Antibodies measured by IF seem to return,
as for E. chaffeensis, to baseline level within 2 years of
infection (S. Dumler, personal communication). Cur-
rently published studies have been done by investigators
using their own slides, prepared by experimental
infection of horses or sheep. Commercial slides are
available but are not useful for diagnosis of human
infection (own observations). The recent in vitro
culture of the HGE agent in HL60 cells, a human
leukemia cell line, will facilitate serodiagnosis and
experimental studies [183]. PCR is a useful tool for
the diagnosis of current infection [159]. Immunoblot
studies of HGE show a specific band at 44 kDa,
identified in all human convalescent sera, and additional
bands at 100, 42 and 25 kDa [184]. ELISA has not been
used for diagnosis of human disease but an ELISA has
been described for antibody response to E. equi
infection in horses [185].
BABESIOSIS
The causative agents, Babesia species (phylum Apicom-
plexa), which are pear-shaped, malaria-like, protozoan
parasites, represent a major veterinary pathogen world-
wide [186]. The parasite was named after Victor Babes,
a Hungarian naturalist, who in 1888 described an
intraerythrocytic pathogen causing febrile hemo-
globinuria in cattle in Transsylvania, present-day
Rumania [187]. The piroplasms are represented by two
families, the Babesiidae and the Theileriidae. The two
differ in target cells, most Babesia species multiplying
only in erythrocytes, while Theileria species first invade
lymphocytes before invading erythrocytes. They also
differ in the mode of replication in ticks. Recent
phylogenetic analyses indicate that some of the agents
currently classified as babesiae are more closely related
to theileriae, and reclassifications have been proposed
[188,189].
More than 100 Babesia species are known but only
two, Babesia divergens in Europe and Babesia microti in
the USA, have until recently been shown to cause
disease in humans. Of these, Babesia divergens belongs
to the classical babesiae, while Babesia microti is a
more Theileria-like organism. In 1991, a Babesia species
causing human disease, designated WA1, was described
from California and was subsequently shown to be a
new species, related to but different from Babesia gibsoni
[190). Then, in 1996, a strain resembling but not
identical to Babesia divergens, designated MOl, was
isolated from a fatal case in a splenectomized patient in
Missouri, USA [191].
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Babesia divergens
The first human case of babesiosis was described in
1957 from Yugoslavia, a fatal case of Babesia divergws
infection in a splenectomized farmer [192]. Since then,
some 25 clinical cases ofBabesia divergens infections have
been described from all parts of Europe [193,194]. A
majority, or some 85%, has occurred in splenectomized
patients and the mortality rate has been about 50%. The
disease is characterized by fever, myalgia, hemolytic
anemia and hemoglobulinuria, with renal failure and
sometimes pulmonary edema in the most severe cases.
The disease has recently been successfully treated by
exchange transfusion in severe cases, in combination
with quinine and clindamycin.
Although Babesia divergens is an important pathogen
in cattle all over Europe, Babesia divergens infection in
immunocompetent individuals has hardly been looked·
for. A congress report from western France indicated
8% asymptomatic seropositives in 408 individuals but
the rate was 2 of 408 (0.5%) if a more conservative cut-
off level of :?:1I80 was used [195]. In a case report
of the first case of Babesia divergens infection in a
splenectomized patient in Sweden, the authors mention
that 13% (2 of 15) of Swedish LB patients were found
to be seropositive to Babesia divergens [196]. Since the
infection rate in immunocompetent individuals has not
been investigated, it is not known if blood-transfusion
transmission could occur.
I. ricinus, the vector of Borrelia burgdoiferi, is also a
vector for Babesia dive~l?ens but others cannot be ruled
out. Cattle represent the obvious reservoir.
Diagnosis of Babesia divergens infection can be made
by identifying intraerythrocytic parasites on blood
smears (to be differentiated from malarial plasmodiae)
in severe cases with a high degree of parasitemia, as
seen in splenectomized patients. Inoculation of gerbils,
which are highly susceptible to Babesia divergens, can
also give the diagnosis. Serologic diagnosis of Babesia
divergens is made by IF on smears from experimentally
infected animals [196]. Antibodies seem to decrease to
base-line levels within a year in the few followed-up
cases [196). Babesia divergens has recently been cultured
in human and animal erythrocytes [197] and in a
serum-free medium supplemented with human high-
density lipoproteins [198]. ELISA for Babesia divergens
has been reported to measure antibodies in bovine sera
[199] but not in human sera. No peR results for
Babesia divergens have been published.
Babesia m;crot;
The European situation, with a rare but severe infection
in immunocompromised individuals, differs markedly
from that in the USA, where more than 400 cases
162 Clinical Microbiology and Infection, Volume 3 Number 2, April 1997
of Babesia microti infections have been described, the
majority in immunocompetent individuals [200).
Recent seroepidemiologic studies in the eastern
USA have indicated infection rates for Babesia microti
varying from 2% in asymptomatic individuals to 7.5%
in individuals with a history of tick bite and fever [200).
Another population study showed seroprevalence rates
for Babesia microti infection of 9% in adults and of 12%
in children [201]. Although babesial infection had
not been diagnosed in any of these individuals, 20-
25% of both adults and children had had clinical
symptoms compatible with the disease during the
previous year.
In Europe, virtually nothing is known about
Babesia microti infections. Sporadic reports have claimed
asymptomatic seropositives for Babesia microti in Europe
(France, southern Germany) but no systematic studies
have been conducted. It is likely that the infection
occurs in immunocompetent individuals also in
Europe, especially as Babesia microti was isolated, several
decades ago, from rodents in both Germany and the
UK [202,203).
In the USA, the most severe, often fatal, infections
ofBabesia microti have been described in splenectomized
patients, as for Babesia divergens infections in Europe.
Babesia microti has been found to cause more severe
disease in older immunocompetent individuals than in
children, which parallels to the clinical spectrum seen
in veterinary medicine. The symptoms in immuno-
competent individuals are uncharacteristic or flu-like as
in ehrlichiosis, with malaise, fatigue, fever, headache,
myalgia, arthralgia, vomiting, depression and emotional
lability as major symptoms [186]. Dark urine is com-
mon, as are mild increases in transaminases. Babesiosis
has been associated with a late-onset adult respiratory
distress syndrome (ARDS) [204]. Chronic infections in
untreated or inadequately treated patients are not
uncommon.
Asymptomatic cases of Babesia microti appear to
recover spontaneously, but the severely ill patients need
treatment with a combination of clindamycin and oral
quinine, which seems to be the most effective regimen.
Chronic infection in asymptomatic individuals
with a low-grade parasitemia has been shown to be
transmitted by blood transfusion [205,206]. Ten cases
have until now been documented from the USA,
including a fatal case of blood-transmitted infection
with a late-onset ARDS.
The vector for Babesia microti is 1. scapularis in the
USA, the same as for Borrelia burgdoiferi and for HGE.
Rodents have been shown to comprise a major
reservoir of Babesia microti in endemic areas. In Europe,
one of the known vectors of Babesia microti is 1. ricinus,
alongside 1. trianguliceps.
The diagnostic methods are the same as for Babesia
divergens, except that the most sensitive experimental
animal was found to be the hamster. Most cases are
diagnosed by serology by IF, and slides are commercially
available [207]. Antibodies decrease to baseline levels
within a year in a majority of cases. PCR for Babesia
microti has been described and is used in diagnosis of
current infection [208]. Attempts to culture Babesia
microti in vitro have so far been unsuccessful [188]. No
ELISA for Babesia microti has been published.
Other babesioses
The clinical picture described for WAl has shown the
same type and range of symptoms, from asymptomatic
to severe clinical disease, as has been described for
Babesia microti [209]. The most severe clinical disease, as
for other babesial infections, occurred in a splenec-
tomized individual. The only case of MOl was a fatal
infection in a splenectomized individual [191], but the
spectrum of the infection caused by this organism has
not, as yet, been established.
The presence of the WAl agent or a related agent
in Europe is suggested by a study, where 14 of 132
(10.6%) of Danish LB patients and 2 of 50 (4%) of
Danish blood donors were found to be seropositive
(K. Hansen, personal communication). It has, however,
to be noted that the specificity of IF for the WAl
piroplasm has not, as yet, been established, in contrast
to IF assays for Babesia divergens and Babesia microti [207],
which have been shown to be specific for the respective
organism, at least in serum dilutions ~1:40-1:80.
Co-transmission and co-infection
Co-transmission of two or several of these agents has
been documented both in Europe and in the USA.
Cases of co-infections with TBEV and Borrelia
burgdOlferi, resulting in a fatal infection in one case, have
been documented [210-212]. As for the other agents,
Ehrlichia and Babesia, clinical investigations in Europe
in human medicine lag vastly behind those in the USA.
In veterinary medicine, however, the aggravating effect
of concurrent infection of looping-ill virus (related to
TBEV) and E. phagocytophila has been known for a long
time [213].
The immunosuppressive effects of both ehrlichial
and babesial infections are well known in veterinary
medicine and are most likely to play an important role
in aggravating other tick-borne infections in humans,
Co-infections might account for the severe, chronic
infections of THEV with only an IgM response. Also,
it remains to delineate the clinical picture of TBEV
infections and to identify the role of ehrlichial and
babesial co-infections, e.g. for the reported thrombo-
cytopenia, leukopenia and elevated transaminases in
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TBE [214], all classical features of the two latter
infections.
Co-infections with the two or three tick-borne
agents, Borrelia burgdOlferi, the HGE agent and Babesia
microti, have recently been suggested from the USA
[215-217]. In the last-quoted study, the authors
estimated the risk of co-infection, if one of the three
infections was diagnosed, to be nearly 1: 10. Similarly,
co-infections, or rather seropositives to both agents,
Borrelia burgdoiferi and the HGE agent, were also found
in the serosurvey on the west coast of Sweden [168].
Several notes of caution are, however, necessary.
Seropositivity in LB by no means represents current
infection. Subclinical or abortive infections can spon-
taneously heal and leave a 'serologic scar' for many
years. Similarly, late treatment of clinical LB may result
in antibodies detectable for many years, if not decades,
after successful treatment and recovery of the patient
[218]. Seropositivity to ehrlichial antigens can persist
for 2 years, while antibodies of high titer to babesial
antigens seem to indicate infection within a year. In
addition, a report of false-positive LB serology, both by
ELISA and by immunoblot, in cases of HGE agent
infections has clear implications for the diagnosis ofLB
and of co-infections of LB and HGE [219].
Nevertheless, there are some reports which seem
to sustain the notion of aggravated infections in the
presence of dual, tick-borne zoonoses. Concurrent
Babesia microti seropositivity was found, in a well-
designed study, to be associated with a more severe
clinical LB, which was also of longer duration than LB
alone [220]. Also, a Danish study (K. Hansen, personal
communication) indicates that 2 of 14 patients with
neuroborreliosis, who were also seropositive for WA1,
had a prolonged disease course and one of the' patients
had elevated liver enzymes.
Tick-borne zoonoses, LB and TBE, are important
infections in Europe, while the roles of the emergent,
new pathogens, Ehrlichia and Babesia, and of co-
infections need to be investigated. The effort should
preferably be made as a collaborative project in Europe
and the network established within the Concerted
Action on Lyme Borreliosis intends to expand its scope
of action to include all these tick-borne zoonoses, with
the ultimate goal of providing optimal prevention and
treatment to patients throughout Europe.
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